Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
E. Kon, Y. Levy, U. Elia, H. Cohen, I. Halevy, M. Aftalion, A. Ezra, E. Bar-Haim, G. S. Naidu, Y. Diesendruck, S. Rotem, N. Ad-El, M. Goldsmith, E. Mamroud, D. Peer, O. Cohen
This study develops an mRNA-LNP vaccine against Yersinia pestis, showing it provides full protection against infection in animals.
bioRxiv · Aug 7, 2022 · PreprintMicrobiology
Y. Vagima, D. Gur, M. Aftalion, S. Moses, Y. Levy, A. Makovitzki, T. Holtzman, Z. Oren, Y. Segula, E. Fatelevich, A. Tidhar, A. Zauberman, S. Rotem, E. Mamroud, I. Steinberger-Levy
This paper shows that combining phage therapy with ceftriaxone improves survival in a mouse model of pneumonic plague caused by multidrug-resistant Yersinia pestis.
bioRxiv · Feb 7, 2022Microbiology
H. Cohen, S. Rotem, U. Elia, G. Bilinsky, I. Levy, T. Chitlaru, E. Bar-Haim
The study assesses T cell responses to the ancestral and Omicron SARS-CoV-2 spike proteins post-BNT162b2 vaccination, finding comparable reactivity and a dominant Th1 response.
bioRxiv · Jan 19, 2022Immunology
N. Madar-Balakirski, A. Rosner, S. Melamed, B. Politi, M. Steiner, H. Tamir, Y. Yahalom Ronen, E. Bar-David, A. Ben-Shmuel, A. Sittner, I. Glinert, S. Weiss, E. Bar-Haim, H. Cohen, U. Elia, , H. Marcus
This study evaluates the safety, immunogenicity, and efficacy of an rVSV-ΔG-SARS-CoV-2-S vaccine in multiple animal species, finding no adverse effects and a robust immune response.
bioRxiv · Jul 6, 2021Pharmacology & Toxicology
U. Elia, S. Rotem, E. Bar-Haim, S. Ramishetti, G. S. Naidu, D. Gur, M. Aftalion, M. Israeli, A. Bercovich-Kinori, R. Alcalay, E. Makdasi, T. Chitlaru, R. Rosenfeld, T. Israely, S. Melamed, , O. Cohen
This study evaluates an mRNA vaccine against SARS-CoV-2 in hACE2 transgenic mice, showing 70% protection against a lethal infection.
bioRxiv · Mar 29, 2021Microbiology